What is the drug of choice for impetigo (impetigo contagiosa) in pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Drug of Choice for Impetigo in Pediatric Patients

Topical mupirocin 2% ointment applied three times daily for 5-7 days is the first-line treatment for localized impetigo in pediatric patients. 1, 2

First-Line Treatment

  • Mupirocin 2% topical ointment is recommended for minor skin infections such as impetigo in children, with application three times daily for 5-7 days 3, 1
  • Clinical efficacy rates for mupirocin in pediatric patients with impetigo are high (78-96%), significantly better than placebo (36%) 2
  • Mupirocin has demonstrated comparable or superior efficacy to oral erythromycin in treating pediatric impetigo with fewer side effects 2, 4
  • Retapamulin 1% ointment applied twice daily for 5 days is an effective alternative for limited impetigo 1

When to Use Oral Antibiotics

Oral antibiotics should be used in the following situations:

  • When impetigo is extensive or involves multiple sites 3, 1, 5
  • When topical therapy is impractical 1, 5
  • When treatment with topical antibiotics has failed 1, 5
  • When systemic symptoms are present 1

Recommended Oral Antibiotic Options

For oral therapy when indicated, options include:

  • For methicillin-susceptible S. aureus (MSSA):

    • Cephalexin: 25 mg/kg/day in 4 divided doses for children 1, 5
    • Dicloxacillin: 12 mg/kg/day in 4 divided doses for children 5
    • Amoxicillin-clavulanate: 25 mg/kg/day of amoxicillin component in 2 divided doses 5
  • For methicillin-resistant S. aureus (MRSA) or when MRSA is suspected:

    • Clindamycin: 10-20 mg/kg/day in 3 divided doses 3, 1, 5
    • Trimethoprim-sulfamethoxazole (TMP-SMX): 8-12 mg/kg/day (based on trimethoprim component) in 2 divided doses 3, 5
    • Note: Tetracyclines (doxycycline, minocycline) should NOT be used in children under 8 years of age 3, 1, 5

Duration of Treatment

  • Topical antibiotics should be used for 5-7 days 1, 5
  • Oral antibiotics should be used for 5-10 days 3, 5
  • Re-evaluation is recommended if no improvement after 48-72 hours of therapy 1, 5

Important Clinical Considerations

  • Cultures should be obtained if there is treatment failure, MRSA is suspected, or in cases of recurrent infections 1, 5
  • Penicillin alone is not effective for impetigo as it lacks adequate coverage against S. aureus 1, 5
  • Mupirocin has shown clinical efficacy against MRSA, but bacterial culture is recommended to rule out resistance 6
  • Keep draining wounds covered with clean, dry bandages to prevent spread 3
  • Maintain good personal hygiene with regular bathing and cleaning of hands 3
  • Avoid reusing or sharing personal items that have contacted infected skin 3

Common Pitfalls and Caveats

  • Topical mupirocin is not formulated for use on mucosal surfaces 2
  • Prolonged use of topical antibiotics may result in overgrowth of nonsusceptible organisms, including fungi 2
  • Rising resistance rates to mupirocin represent a growing concern in some regions 6, 7
  • If impetigo has not improved in 3 to 5 days, consider switching to oral antibiotics or obtaining cultures to guide therapy 5, 2
  • For hospitalized children with complicated skin infections, IV vancomycin or clindamycin may be needed 3

References

Guideline

Treatment of Scalp Impetigo

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Impetigo Refractory to Mupirocin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Interventions for impetigo.

The Cochrane database of systematic reviews, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.